CPT® Code 0537T

Deleted

1. Indications

The indications for performing chimeric antigen receptor T-cell (CAR-T) therapy, specifically the harvesting of blood-derived T lymphocytes for the development of genetically modified autologous CAR-T cells, include the following:

• Hematologic Malignancies Patients with certain types of blood cancers, such as acute lymphoblastic leukemia (ALL) or large B-cell lymphoma, may be candidates for CAR-T therapy.
• Refractory Disease Individuals whose cancer has not responded to standard treatments or has relapsed after initial therapy may be considered for this innovative treatment.
• Specific Antigen Expression Patients whose cancer cells express specific antigens that can be targeted by CAR-T cells are suitable candidates for this therapy.

2. Procedure

The procedure for harvesting blood-derived T lymphocytes for CAR-T therapy involves several critical steps, each designed to ensure the effective collection and preparation of T-cells for genetic modification:

• Step 1: Blood Collection Blood is drawn from the patient, typically through a process known as apheresis, which allows for the selective collection of T-lymphocytes while returning other blood components back to the patient. This process may take place over one or more days, depending on the volume of T-cells required for subsequent engineering.
• Step 2: T-Cell Isolation Once the blood is collected, the T-lymphocytes are separated from the other components of the blood, such as red blood cells and plasma. This isolation is crucial as it ensures that only the T-cells, which will be genetically modified, are retained for the next steps.
• Step 3: Genetic Modification The isolated T-lymphocytes are then subjected to genetic engineering in a laboratory or manufacturing facility. This involves introducing an inactive, genetically modified virus into the T-cells, which enables them to produce chimeric antigen receptors (CARs) on their surface. This step is essential for equipping the T-cells with the ability to recognize and attack cancer cells.
• Step 4: Expansion of CAR-T Cells After the T-cells have been genetically modified, they are expanded and multiplied in the laboratory. This process is critical as it increases the number of CAR-T cells to hundreds of millions, ensuring that there are sufficient cells available for effective treatment upon reinfusion.
• Step 5: Patient Preparation While the CAR-T cells are being manufactured, the patient undergoes lymphocytic cell-depleting chemotherapy. This treatment is designed to reduce the number of existing lymphocytes in the patient’s body, creating a more favorable environment for the newly infused CAR-T cells to thrive and function effectively.
• Step 6: Infusion of CAR-T Cells Once the CAR-T cells are ready and the patient has completed the preparatory chemotherapy, the engineered T-cells are infused back into the patient’s bloodstream. This reinfusion marks the beginning of the CAR-T therapy, as the modified T-cells are now equipped to seek out and destroy cancer cells.

3. Post-Procedure

After the CAR-T cell infusion, patients are closely monitored for any potential side effects or complications that may arise from the treatment. Common post-procedure care includes managing symptoms related to cytokine release syndrome (CRS), which can occur as the CAR-T cells become activated and begin to attack cancer cells. Patients may also require supportive care to address any other adverse effects, such as infections or low blood cell counts, resulting from the lymphodepleting chemotherapy. The duration of recovery and monitoring can vary based on individual patient responses and the specific treatment regimen followed. Additionally, ongoing follow-up appointments are essential to assess the effectiveness of the therapy and to monitor for any signs of cancer recurrence.